A GRAS dossier is often viewed as a regulatory submission prepared solely to support commercialization in the United States. In reality, a well-developed GRAS dossier can become a valuable scientific foundation for regulatory submissions in multiple jurisdictions. Although a U.S. GRAS conclusion does not authorize an ingredient for sale in Canada, the European Union, Australia and New Zealand, or other international markets, much of the underlying scientific evidence—including ingredient identity, manufacturing information, specifications, dietary exposure assessments, toxicology, and supporting literature—may be adapted to support future regulatory submissions.
The extent to which a GRAS dossier can be leveraged depends on the jurisdiction, regulatory pathway, and intended conditions of use. Some sections, such as administrative certifications and regulatory conclusions, are highly jurisdiction-specific and must be rewritten. Others, particularly the core scientific evidence, may provide much of the foundation needed for international market-entry strategies.
Understanding which components of a GRAS dossier can be leveraged—and which require adaptation—can help manufacturers reduce duplication, identify regulatory gaps early, and support a more efficient path toward global commercialization.Join our free webinar, GRAS Under Pressure: Preparing for New FDA Regulations, on September 2 at 1:00 PM ET.
Preparing a Generally Recognized as Safe (GRAS) dossier represents a significant scientific and regulatory investment. Developing the supporting documentation often requires extensive literature reviews, analytical characterization, manufacturing documentation, dietary exposure assessments, toxicological evaluations, and expert review before a company can conclude that an ingredient is generally recognized as safe under its intended conditions of use in the United States.
For many manufacturers, obtaining a GRAS conclusion is viewed as the final milestone before commercializing an ingredient in the U.S. market.
As companies begin expanding internationally, however, a common question quickly follows:
Can the same GRAS dossier be used to support regulatory submissions in other jurisdictions?
The answer is yes—but with an important qualification.
The GRAS conclusion itself does not transfer outside the United States. A self-affirmed GRAS conclusion has no independent legal effect in jurisdictions such as Canada or the European Union, and an FDA “no questions” letter does not authorize an ingredient for sale internationally. Every jurisdiction applies its own legislation, regulatory pathways, scientific guidance, and market authorization requirements.
That does not mean the scientific work completed during a GRAS assessment loses its value.
In fact, a properly prepared GRAS dossier often represents the most comprehensive scientific package an ingredient manufacturer possesses. Information relating to ingredient identity, manufacturing processes, product specifications, analytical characterization, toxicology, human clinical studies, and published scientific literature may all contribute to future regulatory submissions outside the United States.
The key is understanding the difference between a regulatory conclusion and the scientific evidence supporting that conclusion.
While regulatory conclusions are specific to the legal framework under which they were developed, the underlying science frequently addresses many of the same questions asked by food safety authorities around the world.
Rather than rebuilding an entire safety package for every new jurisdiction, companies can often leverage much of their existing scientific evidence while adapting the dossier to satisfy local regulatory expectations.
This article explains which parts of a GRAS dossier can often be leveraged for future submissions, which components typically require modification, and how manufacturers can maximize the value of their regulatory investment when planning international market expansion.
Although a GRAS dossier is prepared within the framework of U.S. food law, the scientific information it contains is not unique to the United States.
Before any regulatory authority can determine whether an ingredient is safe, it must first understand exactly what is being evaluated.
Although regulatory frameworks differ, the scientific principles underlying food safety assessments are often remarkably similar. Regardless of the applicable legislation, regulators generally seek to understand:
These questions arise repeatedly across food safety assessments, even when the legal framework, submission process, and regulatory terminology differ.
For this reason, the greatest long-term value of a GRAS dossier is often not the regulatory conclusion itself, but the scientific evidence assembled to support that conclusion.
A well-developed dossier should contain an extensive compilation of analytical characterization, manufacturing documentation, dietary exposure assessments, toxicological studies, human clinical evidence, and scientific literature reviews.
Reproducing this work for every international submission would often be both costly and unnecessary.
Instead, companies should view a GRAS dossier as a scientific foundation that can support future regulatory strategies.
The objective is rarely to submit the same dossier unchanged. Rather, it is to determine which scientific evidence remains applicable, identify any jurisdiction-specific gaps, and organize that information in a manner that satisfies the expectations of the receiving authority.
Understanding this distinction is the first step toward developing an efficient global regulatory strategy.
One of the most common misconceptions surrounding GRAS is that a successful U.S. regulatory outcome can simply be carried into another jurisdiction.
It cannot.
A GRAS conclusion is a regulatory determination developed under the U.S. Federal Food, Drug, and Cosmetic Act. Whether a company reaches an independent GRAS conclusion or receives an FDA “no questions” letter following a voluntary GRAS Notice, that conclusion applies only within the context of the U.S. regulatory framework and the intended conditions of use that were evaluated.
Other jurisdictions apply different legislation, regulatory definitions, scientific guidance documents, and market authorization pathways.
For example, Canada may first require manufacturers to determine whether an ingredient is considered novel before pursuing a Novel Food Notification or another regulatory pathway. Similarly, ingredients intended for sale in the European Union may require evaluation under the Novel Food Regulation if they meet the applicable definition of a novel food.
Consequently, a GRAS conclusion should not be viewed as an international authorization.
The scientific evidence supporting that conclusion, however, often has much broader value.
Identity and compositional information, manufacturing documentation, product specifications, analytical methods, toxicological studies, published literature, and human clinical evidence frequently address scientific questions that extend well beyond a single regulatory framework.
This does not mean the information can simply be copied into another submission.
Rather, it often provides the scientific foundation upon which future regulatory submissions can be developed.
The extent to which this is possible depends on the jurisdiction, the applicable regulatory pathway, the ingredient itself, and whether the intended conditions of use remain consistent with those originally evaluated.
Understanding this distinction allows manufacturers to focus their efforts on adapting existing scientific evidence to new regulatory requirements rather than recreating work that has already been completed.
Although every GRAS dossier is unique, most follow the same seven-part structure described in FDA’s GRAS notification guidance. Some sections contain administrative information prepared specifically for the U.S. regulatory framework, while others contain the scientific evidence that supports the safety of the ingredient.
Not every section carries the same value when preparing submissions for other jurisdictions.
As a general principle, scientific information relating to an ingredient’s identity, manufacturing process, specifications, and safety frequently provides the greatest long-term value. Administrative documentation, dietary exposure assessments and jurisdiction-specific regulatory conclusions typically require greater adaptation because they are prepared to satisfy the requirements of a particular regulatory authority.
The following table provides a general overview of how the major sections of a GRAS dossier may support future regulatory submissions.
| GRAS Dossier Section | Potential to Support Future Submissions | Typical Adaptation Required |
| Part 1 – Signed Statements and Certification | Low | Administrative documents are generally prepared specifically for the receiving authority. |
| Part 2 – Identity, Method of Manufacture, Specifications, and Physical or Technical Effect | High | Often provides the scientific foundation for future submissions, although manufacturing information and specifications may require updating. |
| Part 3 – Dietary Exposure | Low to Moderate | Exposure assessments frequently require recalculation using local food categories, consumption data, and intended conditions of use. |
| Part 4 – Self-Limiting Levels of Use | Moderate | The underlying scientific rationale may remain relevant, although the concept is not emphasized equally across all regulatory frameworks. |
| Part 5 – Experience Based on Common Use in Food | Moderate | Historical evidence may continue to support safety but often requires supplementation or additional context. |
| Part 6 – Narrative | High | Much of the supporting science may be applied as there is signification overlap in safety requirements in prominent jurisdictions but the regulatory argument is typically rewritten to address local legislation and guidance. |
| Part 7 – Supporting Data and Information | High | Published literature, study reports, analytical data, and toxicological evidence often represent the most valuable scientific assets within the dossier. |
This table should be viewed as a general guide rather than a definitive rule.
The extent to which any section can be leveraged depends on the ingredient, the completeness of the original GRAS dossier, the intended conditions of use, and the expectations of the receiving regulatory authority.
In many cases, the objective is not to submit an existing GRAS dossier unchanged. Instead, the goal is to determine which scientific evidence remains applicable, identify where additional information is required, and organize that evidence to support the regulatory pathway being pursued.
The remainder of this article examines each section of a GRAS dossier in greater detail.
The first section of a GRAS dossier primarily contains administrative information prepared for the U.S. regulatory framework. Depending on whether the dossier supports an independent GRAS conclusion or an FDA GRAS Notice, this section typically includes signed statements, certifications, contact information, intended uses, and declarations regarding the completeness and accuracy of the submission.
From an international perspective, this is generally the least transferable section of a GRAS dossier.
The reason is straightforward.
Administrative documents are prepared to satisfy the procedural requirements of a particular regulatory authority rather than to establish the safety of an ingredient.
Every jurisdiction has its own submission forms, declarations, confidentiality statements, administrative requirements, and legal certifications.
For example, documentation prepared for an FDA GRAS Notice will not satisfy the administrative requirements of Health Canada, the European Commission, or Food Standards Australia New Zealand (FSANZ). Each authority expects submissions to follow its own application procedures and supporting documentation requirements.
Fortunately, replacing these administrative materials typically represents only a small portion of the overall work involved in preparing a new regulatory submission.
The scientific evidence contained throughout the remainder of the dossier is usually far more valuable than the administrative documents used to present it.
If one section of a GRAS dossier provides the greatest long-term value during international market expansion, it is often Part 2.
Before any regulatory authority can evaluate the safety of an ingredient, it must first understand exactly what is being assessed.
Accordingly, regulators around the world generally begin by asking similar questions.
Part 2 typically answers these questions by providing information relating to:
Unlike administrative documents, this scientific information rarely becomes obsolete simply because a company enters a new market.
A detailed manufacturing description prepared for a GRAS dossier may continue to support future submissions provided the commercial manufacturing process remains unchanged.
Similarly, analytical methods used to characterize the ingredient, establish purity, verify specifications, or identify contaminants often remain applicable regardless of the regulatory authority reviewing the submission.
This does not mean Part 2 can always be incorporated without modification.
Different jurisdictions may request additional manufacturing information, supplementary analytical data, updated specifications, or documentation prepared in accordance with local guidance. Manufacturing changes introduced after completion of the original GRAS dossier may also require the information to be updated before it can support another submission.
Nevertheless, Part 2 frequently provides the scientific foundation upon which future regulatory submissions are built.
Rather than recreating manufacturing documentation for every jurisdiction, companies can often leverage this existing body of evidence while supplementing it to address jurisdiction-specific expectations.
Safety cannot be evaluated without understanding consumer exposure.
An ingredient that is safe at one level of consumption may not necessarily be safe if exposure increases significantly or if it is used in different food categories, by different populations, or under different conditions of use.
For this reason, Part 3 evaluates anticipated dietary exposure based on the proposed food uses, maximum use levels, expected serving sizes, frequency of consumption, and available food consumption data.
Although these scientific principles remain consistent across jurisdictions, the assumptions used to calculate dietary exposure often do not.
Food classification systems differ.
Consumption databases differ.
Consumer eating patterns differ.
As a result, dietary exposure assessments are among the most frequently adapted components of a GRAS dossier during international market expansion.
The toxicological evidence supporting the ingredient may remain unchanged.
The exposure assessment used to interpret that evidence often does not.
For example, an exposure assessment prepared using U.S. food consumption data may not accurately represent anticipated intake in Canada, the European Union, or another jurisdiction. Likewise, an ingredient proposed for additional food categories internationally may require new exposure scenarios that were not considered in the original GRAS assessment.
Rather than viewing this as a limitation, manufacturers should view the original exposure assessment as the starting point for future work.
The overall methodology, assumptions, and scientific approach developed during the GRAS assessment frequently provide an excellent framework for preparing revised exposure calculations using jurisdiction-specific consumption data and proposed conditions of use.
Part 4 of a GRAS dossier addresses whether there are practical factors that naturally limit how much of an ingredient can be added to food.
In some cases, an ingredient may impart an undesirable taste, aroma, texture, or other characteristic before it reaches a level that could raise safety concerns. These practical limitations are referred to as self-limiting levels of use and may provide additional context for the intended conditions of use described in the dossier.
Not every ingredient has self-limiting properties, and not every GRAS dossier contains an extensive discussion of this topic.
From an international perspective, the scientific rationale presented in Part 4 may still be useful, even though the concept is not emphasized equally across every regulatory framework.
Regulators are ultimately interested in understanding how an ingredient will be used in practice. Information demonstrating that functional or sensory characteristics naturally limit use levels may therefore help support the overall exposure assessment and intended conditions of use, regardless of jurisdiction.
However, companies should not assume that a discussion of self-limiting use in a GRAS dossier satisfies the expectations of another regulatory authority.
Different jurisdictions may place greater emphasis on proposed maximum use levels, anticipated dietary exposure, technological need, or other considerations when evaluating an ingredient.
Consequently, Part 4 should generally be viewed as supporting scientific information rather than a section that can be transferred directly into another submission.
Part 5 provides an opportunity to support a GRAS conclusion through experience based on common use in food before January 1, 1958.
In practice, relatively few modern GRAS dossiers rely on this approach.
Most contemporary GRAS conclusions are supported through scientific procedures rather than historical evidence of common food use. Establishing widespread consumption before 1958 often requires historical documentation that is difficult to obtain and may not be applicable to many novel ingredients entering today’s food supply.
Nevertheless, evidence relating to historical food use can remain valuable during international regulatory assessments.
Many regulatory authorities consider an ingredient’s history of consumption as one component of an overall safety evaluation. Evidence demonstrating that an ingredient has been consumed safely for many years—particularly when combined with modern toxicological and analytical data—may strengthen the overall scientific package.
The extent to which historical evidence can support a future submission depends on the applicable regulatory framework.
Some jurisdictions establish specific legal definitions of historical use or traditional food use.
Others consider historical consumption as one factor among many within a broader safety assessment.
Accordingly, historical evidence compiled during preparation of a GRAS dossier may often contribute to future submissions, but it frequently requires additional context or supplementation to address jurisdiction-specific regulatory expectations.
Part 6 is often considered the scientific core of a GRAS dossier.
This section brings together the available evidence into a comprehensive narrative explaining why qualified experts can conclude that the ingredient is generally recognized as safe under its intended conditions of use.
Rather than presenting individual studies in isolation, the narrative evaluates the totality of the available evidence.
This may include discussions relating to:
From an international perspective, Part 6 often provides one of the most valuable foundations for future regulatory submissions.
The underlying science frequently remains applicable.
The regulatory argument usually does not.
A GRAS narrative is written to support a conclusion under the U.S. Federal Food, Drug, and Cosmetic Act.
Other jurisdictions ask different legal and regulatory questions.
Although the supporting studies may remain the same, the way those studies are presented, interpreted, and organized often changes to align with local legislation, regulatory guidance, and scientific expectations.
For this reason, companies should generally expect the narrative to be rewritten rather than simply copied into another submission.
The objective is not to recreate the science.
It is to reorganize the existing evidence into a regulatory argument that addresses the requirements of the receiving authority.
When a GRAS dossier has been prepared thoroughly, much of the scientific analysis already exists.
The effort involved in preparing future submissions often focuses on adapting that analysis rather than repeating it.
The final section of a GRAS dossier contains the scientific evidence supporting the conclusions presented throughout the dossier.
Depending on the ingredient, Part 7 may include:
For many manufacturers, this section represents the most valuable long-term asset within the entire dossier.
Scientific studies do not lose their relevance simply because a company enters another market.
A well-designed toxicology study, analytical characterization, or human clinical trial may continue to support regulatory submissions in multiple jurisdictions provided the study remains applicable to the ingredient, manufacturing process, and intended conditions of use.
Additional studies may still be required, although in general, there is extensive overlap in what is considered sufficient safety evidence for a novel ingredient
A receiving authority may request supplemental toxicology, revised analytical data, updated specifications, or new exposure assessments based on the applicable regulatory framework.
However, existing studies frequently provide much of the scientific evidence needed to support those future submissions.
Rather than beginning with an empty dossier, companies often begin with an established body of scientific evidence that can be supplemented where necessary.
This distinction can significantly reduce duplication while helping ensure that future submissions remain scientifically consistent across multiple markets.
International expansion is often considered only after an ingredient has been successfully commercialized in the United States.
By that stage, companies may discover that additional analytical work, manufacturing documentation, or exposure assessments are needed before entering another jurisdiction.
A more efficient approach is to consider potential international markets during the earliest stages of regulatory planning.
When global commercialization is anticipated from the outset, it is often possible to develop a GRAS dossier that serves not only as the basis for a U.S. GRAS conclusion, but also as the scientific foundation for future submissions elsewhere.
This does not mean preparing every international submission in advance.
Rather, it means developing robust scientific documentation that can support multiple regulatory strategies over time.
Planning ahead cannot eliminate jurisdiction-specific regulatory requirements.
It can, however, reduce unnecessary duplication and improve the efficiency of future regulatory submissions.
Common Mistakes When Expanding Internationally
Companies seeking to leverage an existing GRAS dossier often encounter similar challenges.
Some of the most common include:
Assuming a GRAS conclusion applies internationally.
A GRAS conclusion is specific to the U.S. regulatory framework and does not authorize an ingredient for sale in other jurisdictions.
Treating the entire dossier as directly transferable.
While much of the supporting science may remain applicable, regulatory conclusions, administrative documentation, and exposure assessments often require adaptation.
Repeating scientific work unnecessarily.
Manufacturers sometimes assume that entirely new studies must be conducted for every market, even when existing scientific evidence may already address many of the relevant safety questions.
Waiting too long to consider international expansion.
Considering future regulatory pathways early in product development often allows manufacturers to develop scientific evidence that can support multiple submissions over the commercial life of the ingredient.
Join dicentra on September 2 at 1:00 PM ET for GRAS Under Pressure: Preparing for New FDA Regulations, a free webinar examining FDA’s proposed mandatory GRAS notification framework and what it could mean for industry.
Dylan Fronda, Toxicology and Product Safety Manager at dicentra, will discuss the implications for existing GRAS dossiers, FDA review and public disclosure, the proposed streamlined submission pathway, and how companies can participate in the public comment period before the December 9 deadline.
A well-prepared GRAS dossier represents more than a regulatory milestone for the United States—it can become the scientific foundation for future market expansion.
Our GRAS consulting and scientific capabilities include:
dicentra helps ingredient manufacturers evaluate how existing GRAS dossiers can support regulatory submissions in jurisdictions around the world. Our team performs gap assessments, identifies which scientific evidence can be leveraged, determines where additional information may be required, and develops regulatory strategies tailored to the requirements of each target market.
Whether your next market is Canada, the European Union, Australia and New Zealand, or another international jurisdiction, developing the right strategy early can help reduce duplication, streamline future submissions, and maximize the value of the scientific investment already made.
Contact dicentra to discuss your GRAS expansion strategy.